ID   MM253-12M
AC   CVCL_D849
DR   cancercelllines; CVCL_D849
DR   Wikidata; Q54906085
RX   PubMed=669848;
RX   PubMed=6163526;
RX   PubMed=7060019;
CC   Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; LPAM; Alkeran).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2604 ! MM253
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 15
//
RX   PubMed=669848; DOI=10.1002/ijc.2910210407;
RA   Parsons P.G., Morrison L.E.;
RT   "Melphalan-induced chromosome damage in sensitive and resistant human
RT   melanoma cell lines.";
RL   Int. J. Cancer 21:438-443(1978).
//
RX   PubMed=6163526;
RA   Parsons P.G., Carter F.B., Morrison L.E., Dunne R.M.;
RT   "Mechanism of melphalan resistance developed in vitro in human
RT   melanoma cells.";
RL   Cancer Res. 41:1525-1534(1981).
//
RX   PubMed=7060019;
RA   Parsons P.G., Smellie S.G., Morrison L.E., Hayward I.P.;
RT   "Properties of human melanoma cells resistant to
RT   5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other
RT   methylating agents.";
RL   Cancer Res. 42:1454-1461(1982).
//